Norditropin FlexPro 15 mg / 1.5 ml Growth Hormone Pen

• Brand: Novo Nordisk
• Content: 15 mg recombinant somatropin per 1.5 ml (10 mg/ml)
• Manufactured in: Europe

Product Overview

Norditropin FlexPro delivers 191-amino-acid recombinant somatropin (rDNA origin) in a single-use, pre-filled growth hormone pen designed for precision subcutaneous administration in controlled research. Each 1.5 ml pen contains 15 mg of somatropin (10 mg/ml concentration), with a molecular weight of 22,125 Da, formulated for research into growth-hormone deficiency (GHD), body composition shifts, and IGF-1-mediated regeneration.

Post-activation, the FlexPro pen remains stable at 25°C for 3 weeks or 2–8°C for 4 weeks, allowing convenient field-based protocols. Trials show robust support for lean-mass gain, height velocity normalization in pediatric GHD, and erythropoietic stimulation via the IGF-1 axis. All use is governed by WADA Prohibited List S2 due to doping relevance.

Key Research Highlights

• Paediatric growth acceleration: Clinical data confirm normalized height velocity within 6 months in GHD subjects [NovoMedLink, FDA]
• Body composition support: Studies in adult GHD cohorts show lean mass and fat mass after 6–12 months [Norditropin.com]
• Erythropoietic enhancement: Somatropin elevates IGF-1 and erythropoietin, improving haemoglobin levels [FDA Access Data]
• Convenient storage: Remains stable for 3 weeks at 25°C after first use — ideal for outpatient settings [Norditropin.com]

Suggested Laboratory Applications

Growth-hormone deficiency (GHD) modeling in pediatric and adult cohorts

Somatropin-driven body recomposition and lean-mass trials

IGF-1 mediated bone mineralization and BMD research

Erythropoiesis and hematologic growth factor studies

Subcutaneous peptide delivery system evaluation

Technical Specifications

Detection Window

Varies based on dosage and clearance pathway

Documented Benefits

Growth velocity, lean mass, fat mass, BMD, EPO/IGF-1

Main Risks

Edema, injection-site rash, arthralgia, insulin resistance, rare intracranial hypertension

Total Active Compound

15 mg somatropin per pen (10 mg/ml 1.5 ml)

Shelf-life

30 months (refrigerated, unopened); 3–4 weeks post-activation

PubChem-Supported Research Insights

Stimulates linear growth in pediatric GHD models

Enhances protein synthesis and lean mass retention in adult GHD

Modulates IGF-1 axis to support bone density improvements

Shown to improve red blood cell production via EPO stimulation

Offers convenient subcutaneous delivery with high compliance

Documented Research Side Effects

Mild: Edema, arthralgia, injection-site rash

Moderate: Hyperglycaemia and reduced insulin sensitivity

Rare: Intracranial hypertension in long-term studies

Storage and refrigeration required to prevent protein degradation

Handling & Compliance

For Research Use Only — Not for human or veterinary treatmentStore refrigerated at 2–8°C (unopened); post-activation use within 3 weeks at 25°CUse only with NovoFine or NovoTwist 8 mm single-use needlesListed on WADA Prohibited List S2 — peptide hormone; exposure triggers anti-doping violations